Cancer Stem Cell News Volume 10.30 | Aug 4 2021


    2021-08-04 | CSCN 10.30

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 10.30 – 4 August, 2021

    A STAT5B-CD9 Axis Determines Self-Renewal in Hematopoietic and Leukemic Stem Cells

    Scientists found STAT5B to be specifically activated in HSCs and leukemic stem cells, where it induced many genes associated with quiescence and self-renewal, including the surface marker CD9.

    Be sure the cells you’re gene editing are still HSPCs with StemSpan™ SFEM II culture medium.
    PUBLICATIONSRanked by the impact factor of the journal

    Simultaneous CK2/TNIK/DYRK1 Inhibition by 108600 Suppresses Triple Negative Breast Cancer Stem Cells and Chemotherapy-Resistant Disease

    The authors described a novel multi-kinase inhibitor, 108600, that suppressed growth, colony and mammosphere forming capacity of breast cancer stem cell-like cells and induced G2M arrest and apoptosis of triple-negative breast cancer cells.
    [Nature Communications]

    Full Article

    Identification of Cis-HOX-HOXC10 Axis as a Therapeutic Target for Colorectal Tumor-Initiating Cells without APC Mutations

    Circular RNA stabilizing HOXC10 (cis-HOX) was robustly expressed in colorectal tumor-initiating cells (TICs). cis-HOX knockout decreased colorectal TIC numbers and impaired the self-renewal, tumorigenesis, and metastatic capacities of TICs, whereas cis-HOX overexpression drove colorectal TIC self-renewal and metastasis.
    [Cell Reports]

    Full ArticleGraphical Abstract

    β-Catenin-CCL2 Feedback Loop Mediates Crosstalk between Cancer Cells and Macrophages That Regulates Breast Cancer Stem Cells

    Macrophages co-cultured with breast cancer cells showed a significant increase in CCL2 expression and promoted β-Catenin-induced breast cancer stem cells (BCSCs) properties, whereas depletion of CCL2 by adding neutralizing antibodies suppressed BSCSs properties.


    RNF141 Interacts with KRAS to Promote Colorectal Cancer Progression

    The authors examined the expression of RNF141 in 64 pairs of colorectal cancer and adjacent normal tissues by real-time PCR, Western blot, and immunohistochemical analysis.

    Full Article

    PIK3R3, Part of the Regulatory Domain of PI3K, Is Upregulated in Sarcoma Stem-Like Cells and Promotes Invasion, Migration, and Chemotherapy Resistance

    To identify drivers of sarcoma cancer stem-like cells, investigators compared gene expression using RNA sequencing between HT1080 fibrosarcoma and SK-LMS-1 leiomyosarcoma spheroids compared with the parent populations.
    [Cell Death & Disease]

    Full Article

    Sublethal Doxorubicin Promotes Migration and Invasion of Breast Cancer Cells: Role of Src Family Non-Receptor Tyrosine Kinases

    Researchers showed that sublethal doxorubicin treatment led to increased migration and invasion in otherwise non-invasive MCF7 breast cancer cells.
    [Breast Cancer Research]

    Full Article

    Development and In Vitro Characterisation of an Induced Pluripotent Stem Cell Model of Ovarian Cancer

    An ovarian cancer cell line, PEO4, was initially reprogrammed into induced pluripotent stem cells using the classical four factors OCT4, SOX2, KLF4 and MYC using lentivirus transduction.
    [International Journal of Biochemistry & Cell Biology]

    AbstractGraphical Abstract

    The Synergistic Anticancer Traits of Graphene Oxide Plus Doxorubicin Against BT474 and MCF7 Breast Cancer Stem Cells In Vitro

    Different concentrations of doxorubicin (DOX), graphene oxide, and graphene oxide plus doxorubicin (GO-DOX) were subjected to MCF7 and BT474 human breast cancer cells at specified intervals.
    [Applied Biochemistry and Biotechnology]

    Guide to everything you need to know about cell separation.

    Cellular Senescence or Stemness: Hypoxia Flips the Coin

    Investigators discuss the role of hypoxia facilitating senescence bypass during malignant transformation and acquisition of stemness properties, which all contribute to tumor development and cancer disease aggressiveness.
    [Journal of Experimental & Clinical Cancer Research]

    Full Article

    Calidi Biotherapeutics Announces Agreement with Northwestern University for Exclusive Commercial Rights to Their IND for Treatment of Malignant Glioma

    Calidi Biotherapeutics, Inc., announced that it has executed a license agreement with Northwestern University for the exclusive commercialization rights to the IND and data generated from Northwestern’s Phase 1 clinical trial treating brain tumor patients with an engineered oncolytic adenovirus delivered by neural stem cells.
    [Calidi Biotherapeutics, Inc.]

    Press Release

    Ambrx Announces First Patient Dosed in a Phase I Trial for ARX517, an ADC in Development to Treat PSMA Expressing Tumors

    Ambrx announced the first patient has been dosed in a Phase I, multicenter, open-label, dose-escalation, and dose expansion study to evaluate the safety, pharmacokinetics, and anti-tumor activity of ARX517 in subjects with prostate specific membrane antigen (PSMA) expressing tumors found in prostate, pancreatic, lung and ovarian cancers.
    [Ambrx (BusinessWire, Inc.)]

    Press Release


    Colorectal Cancer

    October 21 – 22, 2021

    > See All Events


    Head of Clinical Excellence – Early Oncology Development and Clinical Research

    Pfizer, Inc. – Boulder, Colorado; New York City, New York; San Francisco, California, United States

    Postdoctoral Fellow – Prostate Cancer

    The University of British Columbia – Vancouver, British Columbia, Canada

    Research Associate – Pancreatic, Colon and Lung Cancers.

    Westwood Bioscience, Inc. – Los Angeles, California, United States

    Postdoctoral Fellow – Cancer Genomics and Liquid Biopsies

    University of Gothenburg – Gothenburg, Sweden

    Postdoctoral Scientist – Skin Cancer and Aging

    CRUK Manchester Institute – Manchester, England, United Kingdom

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter